데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
1624602-30-7O=[N+]([O-])c1ccc(S(=O)(=O)N2CCN(c3ccnc4cc(Cl)ccc34)CC2)c([N+](=O)[O-])c1PDQVZPPIHADUOO-UHFFFAOYSA-N1624602-30-7CHEMBL6192451안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요VR23 is a chloroquine derivative that functions as a proteasome inhibitor (IC50s = 1 nM, 50-100 nM, and 3 μM for trypsin-like, chymotrypsin-like, and caspase-like proteasomes, respectively). It also deregulates the activity of cyclin E and other centrosomal proteins, resulting in the induction of multiple centrosome amplification, abnormal spindle formation, uneven cytokinesis, irreversible mitotic arrest, and eventually apoptosis that is specific to cancer cells. In combination with the chymotrypsin-like proteasome inhibitor bortezomib , VR23 can produce a synergistic effect in killing multiple myeloma cells, including those that are resistant to bortezomib.
용도VR23 is a quinoline-sulfonyl hybrid proteasome inhibitor which is used in cancer therapeutics. Targets cancer via cycline E-mediated centrosome.
불러오는 중…
불러오는 중…
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…